Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Denis M Collins"'
Autor:
Neil T Conlon, Sandra Roche, Amira F Mahdi, Alacoque Browne, Laura Breen, Johanna Gaubatz, Justine Meiller, Fiona O'Neill, Lorraine O'Driscoll, Mattia Cremona, Bryan T Hennessy, Lisa D Eli, John Crown, Denis M Collins
Publikováno v:
Translational Oncology, Vol 49, Iss , Pp 102073- (2024)
Background: HER2-targeted therapies have revolutionised the treatment of HER2-positive breast cancer. However, de novo resistance or the emergence of acquired resistance is a persistent clinical problem. Here we report that neratinib, an irreversible
Externí odkaz:
https://doaj.org/article/80c2e8e9bf2e4172bafb263c57f5769f
Autor:
Sandra Roche, Patricia Gaule, Deirdre Winrow, Nupur Mukherjee, Fiona O'Neill, Neil T Conlon, Justine Meiller, Denis M Collins, Alexandra Canonici, Mohammed Ibrahim Fawsi, Alejandra Estepa-Fernández, Stephen F Madden, John Crown, Norma O'Donovan, Alex J Eustace
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0282512 (2023)
Triple Negative Breast Cancer (TNBC), a subtype of breast cancer, has fewer successful therapeutic therapies than other types of breast cancer. Insulin-like growth factor receptor 1 (IGF1R) and the Insulin receptor (IR) are associated with poor outco
Externí odkaz:
https://doaj.org/article/b9644b158fb94f80a2b68dadca1eef19
Autor:
John Crown, Denis M. Collins, Alex J. Eustace, Maccon Keane, Linda Coate, John Kennedy, Seamus O’Reilly, Catherine Kelly, Miriam O’Connor, Michael J. Martin, Conleth Murphy, Karen Duffy, Janice Walshe, Thamir Mahgoub, Giuseppe Gullo, Brian Moulton, Alberto Alvarez-Iglesias, Imelda Parker, Bryan Hennessy
Publikováno v:
Cancer Research. 83:P1-11
Background: The addition of trastuzumab (H) to pre-operative chemotherapy in HER2+ breast cancer (H+BC) increases the rate of pathological complete response (pCR). TCH is a widely used adjuvant regimen in early stage H+BC. Lapatinib (L) is a small mo
Publikováno v:
Cancer Research. 83:P1-11
Background: Targeting the human epidermal growth factor receptor (HER) family of tyrosine kinase receptors with small molecule TKIs lapatinib, neratinib and tucatinib, monoclonal antibodies like trastuzumab and more recently with ADCs like T-DM1 and
Publikováno v:
Cancer Research. 83:P3-07
Background: Up to 70% of HER2 over-expressing (HER2+) breast cancers also express estrogen receptor (ER). Dual targeting of HER2 and ER has shown pre-clinical and clinical benefit in HER2+/ER+ breast cancer. Rationale for these combinations is based
Publikováno v:
Cancer Research. 83:P6-12
Introduction: NER is a pan-HER tyrosine kinase inhibitor (TKI) approved for the treatment of HER2+ BC in the adjuvant setting following trastuzumab and in combination with capecitabine for advanced disease. Resistance to small molecule TKIs like NER
Autor:
Giuseppe Gullo, Alex J. Eustace, Alexandra Canonici, Denis M. Collins, Michael J. Kennedy, Liam Grogan, Oscar Breathhnach, John McCaffrey, Maccon Keane, Michael J. Martin, Rajnish Gupta, Gregory Leonard, Miriam O’Connor, Paula M. Calvert, Paul Donnellan, Janice Walshe, Enda McDermott, Kathleen Scott, Andres Hernando, Imelda Parker, David W. Murray, Alice C. O’Farrell, Ashwini Maratha, Patrick Dicker, Mairin Rafferty, Verena Murphy, Norma O’Donovan, William M. Gallagher, Bonnie Ky, Dimitrios Tryfonopoulos, Brian Moulton, Annette T. Byrne, John Crown
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Background: Combining bevacizumab and chemotherapy produced superior response rates compared with chemotherapy alone in metastatic breast cancer. As bevacizumab may cause hypertension (HTN) and increase the risk of cardiac failure, we performed a pil
Externí odkaz:
https://doaj.org/article/dd373e9d21d44deea251f3cc0cedb80b
Autor:
John Crown, Norma O'Donovan, Birgit Bossenmaier, Max Hasmann, Kenneth J. O'Byrne, Bryan T. Hennessy, Lance Liotta, Virginia Espina, Frankie A. Holmes, William M. Gallagher, Darran P. O'Connor, Sinead Toomey, Jo Ballot, Thamir Mahgoub, Anthony M. Davies, Clare Hughes, Kathy A. Gately, Alex J. Eustace, Marion Le Gal, Dalal AlSultan, Nicola Gaynor, Stephen F. Madden, Denis M. Collins
Purpose:Antibody-dependent cell-mediated cytotoxicity (ADCC) is one mechanism of action of the monoclonal antibody (mAb) therapies trastuzumab and pertuzumab. Tyrosine kinase inhibitors (TKIs), like lapatinib, may have added therapeutic value in comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf4c7768992a836dedac2fd912da254
https://doi.org/10.1158/1078-0432.c.6530235
https://doi.org/10.1158/1078-0432.c.6530235
Autor:
John Crown, Norma O'Donovan, Birgit Bossenmaier, Max Hasmann, Kenneth J. O'Byrne, Bryan T. Hennessy, Lance Liotta, Virginia Espina, Frankie A. Holmes, William M. Gallagher, Darran P. O'Connor, Sinead Toomey, Jo Ballot, Thamir Mahgoub, Anthony M. Davies, Clare Hughes, Kathy A. Gately, Alex J. Eustace, Marion Le Gal, Dalal AlSultan, Nicola Gaynor, Stephen F. Madden, Denis M. Collins
Densitometry for Figure 1D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5c28a8ced7a1a30a504ee5a3a0935d5
https://doi.org/10.1158/1078-0432.22479534.v1
https://doi.org/10.1158/1078-0432.22479534.v1
Autor:
John Crown, Norma O'Donovan, Birgit Bossenmaier, Max Hasmann, Kenneth J. O'Byrne, Bryan T. Hennessy, Lance Liotta, Virginia Espina, Frankie A. Holmes, William M. Gallagher, Darran P. O'Connor, Sinead Toomey, Jo Ballot, Thamir Mahgoub, Anthony M. Davies, Clare Hughes, Kathy A. Gately, Alex J. Eustace, Marion Le Gal, Dalal AlSultan, Nicola Gaynor, Stephen F. Madden, Denis M. Collins
Densitometry analysis for Figure 6D/E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774d4bbd29f834a81cfb5467ee2ca08e
https://doi.org/10.1158/1078-0432.22479516.v1
https://doi.org/10.1158/1078-0432.22479516.v1